Substance use disorders can be successfully managed. UPMC Magee provides compassionate care and support to women and their families throughout the recovery process. We offer several different treatment options to best suit you and your family’s needs at the time you are seeking care.
The following providers are available to be part of your team:
The Pregnancy and Women’s Recovery Center (PWRC) offers the region’s first comprehensive outpatient medication for opioid use disorder (MOUD) program specifically designed for women. Participants who are eligible for enrollment receive recovery support and medication, coordination of outpatient wellness appointments such as routine annual gynecological exams and PCP referrals, social services support, and meetings with a certified recovery specialist. The program combines innovative therapies and compassionate care with psychosocial support and education that sets women and their families up for successful futures. The PWRC offers a variety of buprenorphine products including Suboxone, Sublocade, and Vivitrol.
During pregnancy, Magee can offer an inpatient admission to start you on the medication methadone. Your stay will last about 3-5 days on average, and a member of our social work team will help you schedule a follow-up appointment with a methadone clinic near your home.
Because opioids can cross the placenta, all babies with known exposure to opioids during pregnancy are monitored after birth for signs of withdrawal symptoms. When symptoms are present, this is called Neonatal Opioid Withdrawal Syndrome (NOWS). This does not mean babies are “born addicted.” There are many treatment options that will be reviewed with you and available to your baby. Many of these treatment options do not include medication, although some babies still require it.
The Parent Partnership Unit (PPU) enables parents in recovery to share a private room with their baby while the baby is being monitored for symptoms of NOWS.
Learn more about frequently asked questions relating to recovery services.